Tags

Type your tag names separated by a space and hit enter

From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Postgrad Med. 2002 Sep; 112(3 Suppl):18-25.PM

Abstract

Respiratory tract infections are a major health problem worldwide. Streptococcus pneumoniae remains the most prevalent respiratory tract pathogen. Because of the increasing prevalence of antibiotic resistance in S pneumoniae and other respiratory tract pathogens, development of new antibacterials has become necessary to treat infections that no longer respond to commonly used agents. Telithromycin, a ketolide, is a potent new oral agent designed to treat community-acquired respiratory tract infections and is especially effective against S pneumoniae strains that are resistant to penicillins and macrolides.

Authors+Show Affiliations

University of Michigan College of Pharmacy, Ann Arbor, 48106-1065, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19667591

Citation

Carter, Peggy L.. "From Macrolides to Ketolides: what Is Available for the Treatment of Outpatient Respiratory Tract Infections?" Postgraduate Medicine, vol. 112, no. 3 Suppl, 2002, pp. 18-25.
Carter PL. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections? Postgrad Med. 2002;112(3 Suppl):18-25.
Carter, P. L. (2002). From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections? Postgraduate Medicine, 112(3 Suppl), 18-25. https://doi.org/10.3810/pgm.09.2002.suppl19.101
Carter PL. From Macrolides to Ketolides: what Is Available for the Treatment of Outpatient Respiratory Tract Infections. Postgrad Med. 2002;112(3 Suppl):18-25. PubMed PMID: 19667591.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections? A1 - Carter,Peggy L, PY - 2009/8/12/entrez PY - 2002/9/1/pubmed PY - 2009/9/2/medline SP - 18 EP - 25 JF - Postgraduate medicine JO - Postgrad Med VL - 112 IS - 3 Suppl N2 - Respiratory tract infections are a major health problem worldwide. Streptococcus pneumoniae remains the most prevalent respiratory tract pathogen. Because of the increasing prevalence of antibiotic resistance in S pneumoniae and other respiratory tract pathogens, development of new antibacterials has become necessary to treat infections that no longer respond to commonly used agents. Telithromycin, a ketolide, is a potent new oral agent designed to treat community-acquired respiratory tract infections and is especially effective against S pneumoniae strains that are resistant to penicillins and macrolides. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/19667591/From_macrolides_to_ketolides:_What_is_available_for_the_treatment_of_outpatient_respiratory_tract_infections L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.09.2002.suppl19.101 DB - PRIME DP - Unbound Medicine ER -